Alchemab Therapeutics: Alchemab Selected to Access NVIDIA Cambridge-1 Supercomputer to Advance Machine Learning Enabled Antibody Discovery

Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies and immune repertoire-based patient stratification tools, has been

Related Keywords

United Kingdom ,Craig Rhodes ,Jonathan Nugent ,Douglasa Treco ,Jake Galson ,Nvidia ,Life Sciences ,Head Of Technology At Alchemab Therapeutics ,Alchemab Therapeutics ,Chief Executive Officer ,Nvidia Inception ,Investor Relations ,Alchemab ,Herapeutics ,Elected ,Access ,Cambridge ,Supercomputer ,Advance ,Machine ,Learning ,Nabled ,Ntibody ,Discovery ,